Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1.
Richardson
Stephen
S
Department of Dermatology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA.
Budgin
Jeanne B
JB
Junkins-Hopkins
Jacqueline M
JM
Vittorio
Carmela C
CC
Lee
Jason
J
Miller
Wallace T
WT
Rook
Alain H
AH
Kim
Ellen J
EJ
D000284:Administration, Oral; D000077610:Bexarotene; D001707:Biopsy, Needle; D001774:Blood Chemical Analysis; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D018570:Risk Assessment; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene